A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019

A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019 Publisher

Shabani M¹ ; Sadegh Ehdaei B² ; Fathi F³ ; Dowran R¹

Show Affiliations

1. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2. Microbiology and Immunology Department, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: New Microbes and New Infections Published:2021

Abstract

Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. © 2021 The Authors

Related Docs

View other Related Docs

1. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)

2. Potential Nephrotoxicity of Sofosbuvir-Based Treatment in Patients Infected With Hepatitis C Virus: A Review on Incidence, Type and Risk Factors, Expert Review of Clinical Pharmacology (2018)

3. Safely Treating Hepatitis C in Patients With Hiv or Hepatitis B Virus Coinfection, Expert Opinion on Drug Safety (2015)

4. A Theoretical Strategy for Acceleration of Human Immune Response Against Sars-Cov-2: A Fusion Protein Harboring Virus-Binding and Pre-Exposed Antigen Domains, VirusDisease (2021)

5. Severe Acute Respiratory Syndrome-Coronavirus-2 Spike (S) Protein Based Vaccine Candidates: State of the Art and Future Prospects, Reviews in Medical Virology (2021)

6. The Emerging Role of Probiotics As a Mitigation Strategy Against Coronavirus Disease 2019 (Covid-19), Archives of Virology (2021)

7. Is There Still Hope for the Prophylactic Hepatitis C Vaccine? a Review of Different Approaches, Journal of Medical Virology (2024)

8. The Possible Role of Novel Coronavirus 2019 Proteins in the Development of Drugs and Vaccines, Journal of Applied Biotechnology Reports (2020)

Experts (# of related papers)

View all Related Experts

Reza Malekzadeh (3)

Hossein Poustchi (3)

Style	Citing Format
MLA	Shabani M, et al.. "A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019." New Microbes and New Infections, vol. 42, no. , 2021, pp. -.
APA	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R (2021). A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019. New Microbes and New Infections, 42(), -.
Chicago	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. "A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019." New Microbes and New Infections 42, no. (2021): -.
Harvard	Shabani M et al. (2021) 'A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019', New Microbes and New Infections, 42(), pp. -.
Vancouver	Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019. New Microbes and New Infections. 2021;42():-.
BibTex	@article{ author = {Shabani M and Sadegh Ehdaei B and Fathi F and Dowran R}, title = {A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019}, journal = {New Microbes and New Infections}, volume = {42}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Shabani M AU - Sadegh Ehdaei B AU - Fathi F AU - Dowran R TI - A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019 JO - New Microbes and New Infections VL - 42 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract